急性冠脉综合征患者补体水平的动态变化及其与心肌损伤的关系
该回顾性分析纳入170例ACS患者(110例STEMI、60例NSTE-ACS)及36例健康对照,检测入院第1、3、7天血清补体C3、C4、C5b-9水平及心肌功能指标,随访1年分析MACE和再入院率。结果示ACS两组第1天补体水平均显著高于对照,STEMI组第3天达峰且第3、7天C4和C5b-9高于NSTE-ACS组。GRACE高危组补体水平显著高于低、中危组且LVEF最低。Pearson分析示补体与TnT、sICAM-1正相关,与LVEF负相关。结论认为补体激活参与ACS急性期心肌损伤过程,可能反映心肌损伤和心功能障碍的严重程度。
要点
- ACS患者入院第1天血清C3、C4、C5b-9均显著高于健康对照(均P<0.05),提示急性期补体激活。
- STEMI组补体于第3天达峰(C3 1.37±0.33 g/L、C4 0.42±0.12 g/L、C5b-9 754.72±136.22 g/L),第3、7天C4和C5b-9高于NSTE-ACS组。
- GRACE>140分高危组TnT、sICAM-1、C3、C4、C5b-9显著高于低危(≤108分)和中危(109-140分)组,且LVEF最低。
- 血清C3、C4、C5b-9与TnT正相关(r=0.481、0.367、0.292,均P<0.01),与LVEF负相关(r=-0.384、-0.260、-0.200,均P<0.01)。
- STEMI与NSTE-ACS两组再入院率和MACE发生率无显著差异。
适用人群与场景
- 因缺血性胸痛或胸部不适发作12小时内入住心内科的ACS患者,包括STEMI 110例和NSTE-ACS 60例。
- 同期36例健康者为对照。
诊断标准与关键阈值
- 按GRACE评分将ACS患者分为低危组(≤108分,26例)、中危组(109-140分,61例)和高危组(>140分,83例)。
研究设计与关键结果
- 回顾性分析,纳入170例ACS患者(STEMI 110例、NSTE-ACS 60例)及36例健康对照,检测入院第1、3、7天血清C3、C4、C5b-9及心肌功能指标,随访1年。
- 第1天NSTE-ACS组和STEMI组C3、C4、C5b-9均高于对照组[C3(g/L):1.04±0.33、1.26±0.35 vs 0.39±0.21;C4(g/L):0.31±0.14、0.33±0.10 vs 0.19±0.07;C5b-9(g/L):575.46±197.26、659.26±160.77 vs 501.40±141.51,均P<0.05]。
- NSTE-ACS组C3、C4无变化,C5b-9在第3天达峰(700.63±218.42 g/L)后下降;STEMI组补体第3天达峰[C3 1.37±0.33 g/L、C4 0.42±0.12 g/L、C5b-9 754.72±136.22 g/L]。
- STEMI组第3、7天C4和C5b-9高于NSTE-ACS组。
- STEMI组TnT、CK-MB、sICAM-1、GRACE评分和PCI例数显著高于NSTE-ACS组,LVEF相反;两组NT-proBNP、Fib、再入院率和MACE发生率无显著差异。
- 中危组TnT和sICAM-1显著高于低危组;高危组TnT、sICAM-1、C3、C4、C5b-9显著高于低危和中危组,LVEF最低。
- Pearson相关分析:C3、C4、C5b-9与TnT正相关(r=0.481、0.367、0.292,均P<0.01),与sICAM-1正相关(r=0.298、0.249、0.365,均P<0.01),与LVEF负相关(r=-0.384、-0.260、-0.200,均P<0.01);sICAM-1与TnT正相关(r=0.536,P=0.000),与LVEF负相关(r=-0.341,P=0.001)。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血清补体C3、C4、C5b-9参与ACS急性期心肌损伤过程,可能反映心肌损伤和心功能障碍的严重程度。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To study relationships between myocardial injury and the levels of serum complement C3, C4 and C5b-9 in patients with acute coronary syndrome (ACS).
METHODS: A retrospectively analysis was conducted. 170 ACS patients [including 110 cases of ST-segment elevation myocardial infarction (STEMI) and 60 cases of non-ST-segment elevation acute coronary syndrome (NSTE-ACS)] with ischemic chest pain or chest discomfort onset within the prior 12 hours admitted to the cardiology department of Tianjin Union Medicine Center from January 2014 to July 2016 were enrolled. Thirty-six healthy cases were enrolled as control during the same time. The levels of serum complement C3, C4 and C5b-9 on 1, 3 and 7 days after admission and myocardial function indicators were analyzed. Major adverse cardiovascular events (MACE) and readmission rate were analyzed after 1 year follow-up. The correlation between serum complement levels and myocardial function indicators was analyzed by Pearson correlation analysis.
RESULTS: (1) The levels of serum C3, C4 and C5b-9 on the first day in NSTE-ACS group and STEMI group were significantly higher than control group [C3 (g/L): 1.04±0.33, 1.26±0.35 vs. 0.39±0.21, C4 (g/L): 0.31±0.14, 0.33±0.10 vs. 0.19±0.07, C5b-9 (g/L): 575.46±197.26, 659.26±160.77 vs. 501.40±141.51, all P < 0.05]. There were no changes of serum C3, C4 in NSTE-ACS group, but C5b-9 decreased after a peak (g/L: 700.63±218.42) at 3 days. Serum complements in STEMI group reached peak on the third day [C3 (g/L): 1.37±0.33, C4 (g/L): 0.42±0.12, C5b-9 (g/L): 754.72±136.22]. The levels of serum C4 and C5b-9 in STEMI group were higher than NSTE-ACS group on the third and seventh day. (2) The levels of troponin T (TnT), creatine kinase-MB (CK-MB), solution intercellular adhesion molecule-1 (sICAM-1), global registry of acute coronary events (GRACE) scores and percutaneous coronary intervention (PCI) numbers in STEMI group were significantly higher than those in the NSTE-ACS group, which were as opposite as left ventricular ejection fraction (LVEF). However, there were no significant differences in levels of serum N-terminal pro-brain nitric peptide (NT-proBNP), Fibrinogen (Fib), readmission rate and incidence of MACE between STEMI and NSTE-ACS groups. (3) According to GRACE, patients with ACS were divided into low risk group (≤ 108 scores, 26 cases), intermediate risk group (109-140 scores, 61 cases) and highest group (> 140 scores, 83 cases). TnT and sICAM-1 in intermediate risk group were significantly increased as compared with low risk group. Levels of TnT, sICAM-1, C3, C4 and C5b-9 in the highest group were significantly higher than the low and intermediate risk groups, however the lowest LVEF was found in the highest group. (4) It was shown by Pearson correlation analyses that levels of serum C3, C4, C5b-9 were positively correlated with TnT (r value was 0.481, 0.367, 0.292, respectively, all P < 0.01), sICAM-1 (r value was 0.298, 0.249, 0.365, respectively, all P < 0.01), but negatively correlated with LVEF (r value was -0.384, -0.260, -0.200, respectively, all P < 0.01). In addition sICAM-1 positively correlated with TnT (r = 0.536, P = 0.000), but negatively correlated with LVEF (r = -0.341, P = 0.001).
CONCLUSIONS: Serum complements activation was found in the acute phase of ACS patients. Serum complement C3, C4 and C5b-9 are involved in the process of myocardial injury, and may reflect severity of myocardial injury and cardiac dysfunction.
参考来源
- Shao A, Qi X, Li Q, et al. [Dynamic changes of complement level in patients with acute coronary syndrome and its relationships with myocardial injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28625240. doi:10.3760/cma.j.issn.2095-4352.2017.06.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。